Brainstorm Cell Therapeutics hires leading scientist to advisory board
This article was originally published in Clinica
Brainstorm Cell Therapeutics, a firm focused on developing adult stem cell technologies and therapeutics for treatment of neurological conditions, has appointed Robert Brown to its scientific advisory board. Dr Brown, a professor of neurology at Harvard Medical School and Massachusetts General Hospital (MGH), is an expert in amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease). He will help the New York, New York based company develop protocols for testing its lead products as ALS therapies. During his 30 years in the field, he has founded the Cecil Bay Laboratory for neuromuscular research at MGH and had his research published widely. In 2007 he won the Robert Wartenberg Lecture Award for excellence in clinically-relevant research, and will become chair of the medical school at the University of Massachusetts later this year.